Shanghai Sigma-Audley New Material Technology: difference between revisions
Diff·revision 30 → 31·10:22, 4 Apr 2025
Difference between revision 30 and revision 31 of Shanghai Sigma-Audley New Material Technology. 3 lines changed; the page grew by 363 bytes.
| Revision 30 — 12:15, 29 Mar 2025 DrTitration (talk) fix unit 7,057 bytes ±0 | Revision 31 — 10:22, 4 Apr 2025 ForgeryFinder (talk) copyedit 7,420 bytes +363 | ||
|---|---|---|---|
| 49 | Documentation detail reported by purchasers is markedly better for the incretin analogues than for the bulk categories, a gradient visible across most organisations covered on this wiki and probably reflecting where purchaser scrutiny is concentrated.{{r|reports}} | 49 | Documentation detail reported by purchasers is markedly better for the incretin analogues than for the bulk categories, a gradient visible across most organisations covered on this wiki and probably reflecting where purchaser scrutiny is concentrated.{{r|reports}} |
| 50 | 50 | ||
| + | 51 | == Independent testing record == | |
| + | 52 | Submitted reports on SSA material to July 2026 are concentrated on tirzepatide and semaglutide, with a smaller set on repair peptides. Reported [[Area percent purity|area percent]] figures have clustered in the high nineties, and where a certificate accompanied the sample the two figures have generally been close.{{r|reports}} | |
| + | 53 | ||
| 51 | == References == | 54 | == References == |
| 52 | {{reflist}} | 55 | {{reflist}} |